RxDoctor Payments DataLook up a doctor →

Scott Hippeard, MD

General Practice · Roanoke, VANPI 1073625109

Payments from drug & device makers

$7,093in general payments, 2019–2025

Across 450 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$739
  • Lilly USA, LLC$668
  • Novo Nordisk$474
  • Lundbeck LLC$397
  • Pfizer$347
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,062100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,093 in reported general payments places this provider in the 95th percentile of 2,591 general practice providers in Virginia.

See all general practice providers in Virginia

Medicare billing

Part B allowed, 2024
$90,535
Medicare patients
180
Services billed
3,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$49,598
EliquisApixaban42$42,447
TrulicityDulaglutide16$41,184
JanuviaSitagliptin Phosphate19$29,501
XareltoRivaroxaban16$26,790
FarxigaDapagliflozin Propanediol18$26,556
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$19,806
MovantikNaloxegol Oxalate12$9,847
SynthroidLevothyroxine Sodium53$5,289
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,970
Gabapentin83$2,522
Celecoxib46$1,916
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen62$1,868
Nebivolol Hcl23$1,605
Pregabalin27$1,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$474$49,59828 claims
PfizerEliquis$347$42,44742 claims
Lilly USA, LLCTrulicity$668$41,18416 claims
MerckJanuvia$138$29,50119 claims
Johnson & JohnsonXarelto$109$26,79016 claims
AstraZenecaFarxiga$739$26,55618 claims
GSKTrelegy Ellipta$107$19,80611 claims
AbbVieSynthroid$1,495$5,28953 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,591 general practice providers in Virginia.

Other general practice in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →